These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38469649)

  • 1. Mucopolysaccharidosis (MPS IIIA) mice have increased lung compliance and airway resistance, decreased diaphragm strength, and no change in alveolar structure.
    Paget TL; Larcombe AN; Pinniger GJ; Tsioutsias I; Schneider JP; Parkinson-Lawrence EJ; Orgeig S
    Am J Physiol Lung Cell Mol Physiol; 2024 Jun; 326(6):L713-L726. PubMed ID: 38469649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.
    Paget TL; Parkinson-Lawrence EJ; Trim PJ; Autilio C; Panchal MH; Koster G; Echaide M; Snel MF; Postle AD; Morrison JL; Pérez-Gil J; Orgeig S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33918094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice.
    Dwyer CA; Scudder SL; Lin Y; Dozier LE; Phan D; Allen NJ; Patrick GN; Esko JD
    Sci Rep; 2017 Apr; 7():46576. PubMed ID: 28418018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test.
    Langford-Smith A; Langford-Smith KJ; Jones SA; Wynn RF; Wraith JE; Wilkinson FL; Bigger BW
    PLoS One; 2011; 6(10):e25717. PubMed ID: 22028789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
    Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
    Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary culture of neural cells isolated from the cerebellum of newborn and adult mucopolysaccharidosis type IIIA mice.
    Sutherland LM; Hemsley KM; Hopwood JJ
    Cell Mol Neurobiol; 2008 Nov; 28(7):949-59. PubMed ID: 18297392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells.
    Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ
    Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Engineered
    Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
    Mohammed EE; Snella EM; Rutz-Mendicino MM; Echevarria FD; Awedikian R; Whitley EM; Ellinwood NM
    Mol Genet Metab; 2012 Sep; 107(1-2):129-35. PubMed ID: 22867887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
    Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
    Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
    Perkins KJ; Muller V; Weber B; Hopwood JJ
    Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
    Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
    Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early disease course is unaltered in mucopolysaccharidosis type IIIA (MPS IIIA) mice lacking α-synuclein.
    Soe K; Beard H; Neumann D; Trim PJ; Duplock S; Snel MF; Hopwood JJ; Hemsley KM
    Neuropathol Appl Neurobiol; 2019 Dec; 45(7):715-731. PubMed ID: 30907009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA).
    Hassiotis S; Jolly RD; Hemsley KM
    Mol Genet Metab; 2014 Dec; 113(4):283-93. PubMed ID: 25453402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment.
    Arfi A; Richard M; Gandolphe C; Bonnefont-Rousselot D; Thérond P; Scherman D
    Mol Genet Metab; 2011 May; 103(1):18-25. PubMed ID: 21353610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA).
    Hemsley KM; Hopwood JJ
    Behav Brain Res; 2005 Mar; 158(2):191-9. PubMed ID: 15698885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.